ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology

Kyowa Kirin Co., Ltd.

Business Summary

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2022 JPYUSD
Gross Profit301,363M2,291.25M
Operating income82,375M626.29M
Income before tax63,249M480.87M
Net income53,573M407.31M
Diluted EPS99.650.75
Dividends Per Share510.38
Total Assets939,881M7,123.27M
Total liabilities177,055M1,341.88M
Total equity762,826M5,781.39M
Operating cash flow48,672M370.05M
Currency in JPYCurrency in USD

Historical Data

 Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022
Revenue 271,510M 305,820M 318,352M 352,246M 398,371M
Gross Profit 188,834M 215,129M 227,827M 253,894M 301,363M
Operating income 50,403M 53,354M 55,419M 61,110M 82,375M
Income before tax 66,841M 44,492M 52,263M 55,475M 63,249M
Net income 49,230M 37,674M 47,027M 52,347M 53,573M
EBITDA 66,646M 72,151M 75,885M 80,608M 100,851M
Diluted EPS 99.29 43.12 87.49 97.38 99.65
Dividends Per Share 35 42 44 46 51
Total Assets 741,982M 784,453M 801,290M 921,872M 939,881M
Total liabilities 92,589M 106,203M 102,893M 184,710M 177,055M
Total equity 649,621M 678,250M 698,396M 737,162M 762,826M
Operating cash flow 56,181M 53,655M 39,502M 86,548M 48,672M
 Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022
Revenue 2,458.37M 2,805.40M 2,981.70M 3,205.93M 3,028.80M
Gross Profit 1,709.78M 1,973.46M 2,133.84M 2,310.79M 2,291.25M
Operating income 456.37M 489.43M 519.05M 556.18M 626.29M
Income before tax 605.20M 408.14M 489.49M 504.90M 480.87M
Net income 445.75M 345.59M 440.45M 476.43M 407.31M
EBITDA 603.44M 661.87M 710.74M 733.64M 766.76M
Diluted EPS 0.89 0.39 0.81 0.88 0.75
Dividends Per Share 0.31 0.38 0.41 0.41 0.38
Total Assets 6,762.81M 7,218.33M 7,761.05M 8,005.48M 7,123.27M
Total liabilities 843.90M 977.25M 996.59M 1,604.01M 1,341.88M
Total equity 5,920.98M 6,241.08M 6,764.45M 6,401.47M 5,781.39M
Operating cash flow 508.68M 492.19M 369.97M 787.70M 370.05M

Valuation Measures

Dec 2022
Operating margin20.67%
Profit margin13.44%

Key executives

  • President, CEO & Representative Director: Masashi Miyamoto
  • Executive Officer, Manager-Accounting & Finance: Motohiko Kawaguchi
  • Executive Officer, GM-Research & Development: Mitsuo Satoh
  • Representative Director & Executive Vice President: Yutaka Osawa
  • Executive Officer & General Manager-Sales: Hiroshi Sugitani


  • Kirin Holdings Co., Ltd. (53.4%)
  • Nomura Asset Management Co., Ltd. (3.2%)
  • Daiwa Asset Management Co. Ltd. (1.6%)
  • Massachusetts Financial Services Co. (1.5%)
  • Nikko Asset Management Co., Ltd. (1.5%)
  • The Vanguard Group, Inc. (1.2%)
  • BlackRock Fund Advisors (0.9%)
  • Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.8%)
  • Norges Bank Investment Management (0.7%)
  • Goldman Sachs Asset Management Co., Ltd. (Japan) (0.5%)

Contact Details

  • Website:
  • Address: Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Tokyo, 100-0004, Japan
  • Phone: +81.3.5205.7200

Related Companies

  • Kyowa Kirin Australia Pty Ltd.
  • Kyowa Kirin Pharma FZ LLC
  • Kyowa Kirin Malaysia Sdn. Bhd.
  • Kyowa Kirin Korea Co., Ltd.
  • Kyowa Kirin Pharma SRL
  • Kyowa Kirin Pharma sro
  • Kyowa Kirin Austria GmbH
  • Kyowa Kirin SARL
  • Kyowa Kirin AB
  • Kyowa Kirin Pharma BV
  • Kyowa Kirin Holdings BV
  • Kyowa Kirin Farmaceutica SL
  • Kyowa Kirin Ireland Ltd.
  • Kyowa Kirin Canada, Inc.
  • Kyowa Kirin Frontier Co., Ltd.
  • Kyowa Medical Promotion Co., Ltd.
  • Kyowa Kirin GmbH
  • Strakan International SARL
  • Kyowa Kirin Plus Co., Ltd.
  • Kyowa Hakko Bio Co. Ltd. (Beijing)
  • Kyowa Hakko Bio (Shanghai) Trading Co., Ltd.
  • Kyowa Hakko Bio (Shanghai) Trading Co. Ltd. /Beijing Branch/
  • Kyowa Hakko Bio Shanghai Trading Co. Ltd. /Guangzhou/
  • Kyowa Hakko Kirin (Hong Kong) Co. Ltd.
  • Kyowa Hakko Kirin (Taiwan) Co. Ltd.
  • Kyowa Hakko Kirin (Singapore) Pte Ltd.
  • Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin (Thailand) Co. Ltd.
  • ProStrakan SRL
  • Kyowa Hakko Kirin America, Inc.


  • JW Holdings Corporation
  • Genexine, Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • 4d Pharma PLC
  • Vaxxinity Inc Class A
  • Innate Pharma SA Class A
  • FibroGen, Inc.
  • Heron Therapeutics Inc
  • Tetralogic Pharmaceuticals Corporation
  • Citius Pharmaceuticals Inc
  • Ikena Oncology, Inc.
  • Seagen, Inc.
  • Connect Biopharma Holdings Ltd. Sponsored ADR
  • Springworks Therapeutics, Inc.
  • Prometheus Biosciences, Inc
Last Updated on 24 Mar, 2023

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more